Yuen-Yi Tseng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuen-Yi Tseng has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Samuel J. Klempner
Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
23 shared publications - Alexander Caraballo
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 7
22 shared publications - Alice E. Shin
Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, USA
22 shared publications - Andrew T. Chan
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
22 shared publications - Carmen Rios
Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, Boston, Massachusetts. 10
22 shared publications - Chi-Lee C. Ho
Department of Surgery, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. 1
22 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 3 shows the progression of disease between 4and 8 week old TCON mice and the amount of ACTN4 and DPP4 in stomach tissue.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 3 shows the progression of disease between 4and 8 week old TCON mice and the amount of ACTN4 and DPP4 in stomach tissue.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 1 shows the effect using different lysis buffers has on protein identification in stool protein mass spectrometry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 1 shows the effect using different lysis buffers has on protein identification in stool protein mass spectrometry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 2 describes the biopsy information of patient derived organoid cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 2 describes the biopsy information of patient derived organoid cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 1 lists the age and sex of stool donors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 1 lists the age and sex of stool donors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 4 contains heat maps of stool proteins between various stool donor groups and emphasizes the differential abundance of protein profiles based on donor status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 4 contains heat maps of stool proteins between various stool donor groups and emphasizes the differential abundance of protein profiles based on donor status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- Open Access
- 27 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (8)
Identification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma
Translocations involving FGFR2 gene fusions are common in cholangiocarcinoma and predict response to FGFR kinase inhibitors. However, response rates and durability are limited due to the emergence of resistance, typically involving FGFR2 kinase domain mutations, and to suboptimal dosing, relating to drug adverse effects. Here, we develop biparatopic antibodies targeting the FGFR2 extracellular domain (ECD) as candidate therapeutics. Biparatopic antibodies can overcome drawbacks of bivalent monospecific antibodies, which often show poor inhibitory or even agonist activity against oncogenic receptors. We show that oncogenic transformation by FGFR2 fusions requires an intact ECD. Moreover, by systematically generating biparatopic antibodies targeting distinct epitope pairs in FGFR2 ECD, we identified antibodies that effectively block signaling and malignant growth driven by FGFR2 fusions. Importantly, these antibodies demonstrate efficacy in vivo, synergy with FGFR inhibitors, and activity against FGFR2 fusions harboring kinase domain mutations. Thus, we believe that biparatopic antibodies may serve as an innovative treatment option for patients with FGFR2-altered cholangiocarcinoma.
- 27 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (8)
Open AccessIdentification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma
Translocations involving FGFR2 gene fusions are common in cholangiocarcinoma and predict response to FGFR kinase inhibitors. However, response rates and durability are limited due to the emergence of resistance, typically involving FGFR2 kinase domain mutations, and to suboptimal dosing, relating to drug adverse effects. Here, we develop biparatopic antibodies targeting the FGFR2 extracellular domain (ECD) as candidate therapeutics. Biparatopic antibodies can overcome drawbacks of bivalent monospecific antibodies, which often show poor inhibitory or even agonist activity against oncogenic receptors. We show that oncogenic transformation by FGFR2 fusions requires an intact ECD. Moreover, by systematically generating biparatopic antibodies targeting distinct epitope pairs in FGFR2 ECD, we identified antibodies that effectively block signaling and malignant growth driven by FGFR2 fusions. Importantly, these antibodies demonstrate efficacy in vivo, synergy with FGFR inhibitors, and activity against FGFR2 fusions harboring kinase domain mutations. Thus, we believe that biparatopic antibodies may serve as an innovative treatment option for patients with FGFR2-altered cholangiocarcinoma.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.